EMA's PIP class waiver revisions are scientifically sound but may pose legal/ethical issues for companies
This article was originally published in SRA
Executive Summary
The European Medicines Agency's revision of its list of class waivers for pediatric investigation plans (PIPs)may result in legal or ethical challenges for pharmaceutical companies in cases where pediatric trials are requested for diseases with low prevalence in children, according to a legal expert1.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.